Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease

Internal Medicine

Volumn 50, Issue 7, 2011, Pages 687-694

  Nakaoka, Sachiko ^a   Ishizaki, Tatsuro ^a   Urushihara, Hisashi ^a   Satoh, Toshihiko ^b   Ikeda, Shunya ^c   Morikawa, Kaoru ^d   Nakayama, Takeo ^a  

^a KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^d NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Database research; Dopamine agonist; Echocardiography; Parkinson's disease; Safety information; Valvulopathy

Indexed keywords

ANTIPARKINSON AGENT; CABERGOLINE; PERGOLIDE;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG CONTROL; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECHOCARDIOGRAPHY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PARKINSON DISEASE; PATIENT ASSESSMENT; PHYSICIAN ATTITUDE; PRESCRIPTION; RISK ASSESSMENT; TREATMENT DURATION; VALVULAR HEART DISEASE;

ADULT; AGED; DOPAMINE AGONISTS; DRUG LABELING; ECHOCARDIOGRAPHY; ERGOLINES; FEMALE; HEART VALVE DISEASES; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PARKINSON DISEASE; PERGOLIDE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79953740339     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4344     Document Type: Article

References (38)

1. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 353: 1021-1027, 2005.
2. Yamawaki M, Kusumi M, Kowa H, Nakashima K. Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century. Neuroepidemiology 32: 263-269, 2009.
3. Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y. Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 2010. [Epub ahead of print].
4. Miziuno Y, Okuma Y, Kikuchi S, et al. A guideline for the treatment of Parkinson's disease. Rinsho Shinkeigaku 42: 421-494, 2002 (in Japanese).
5. Taniguchi A, Narita Y, Naito Y, Kuzuhara S. An analysis of application form of Parkinson's disease provided by the specific disease treatment research program of Ministry of Health, Labour and Welfare of Japan. Rinsho Shinkeigaku 48: 106-113, 2008 (in Japanese).
6. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77: 1280-1286, 2002.
7. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63: 301-304, 2004.
8. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363: 1179-1183, 2004.
9. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356: 29-38, 2007.
10. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356: 39-46, 2007.
11. Steiger M, Jost W, Grandas F, Van Camp G. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J Neural Transm 116: 179-191, 2009.
12. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67: 1225-1229, 2006.
13. Yamashiro K, Komine-Kobayashi M, Hatano T, et al. The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 23: 935-941, 2008.
14. FDA Public Health Advisory Pergolide (marketed as Permax) [Internet]. Rockville: U.S. Food and Drug Administration; c2007 [cited 2010 Aug 8]. Available from: http://www.fda.gov/Drugs/ DrugSafety/PublicHealthAdvisories/ucm051285.html
15. "Important Precautions" Revised information [Internet]. Tokyo: Ministry of Health, Labour and Welfare; c2007 [cited 2010 Aug 8] (in Japanese). Available from: http://www.info.pmda.go.jp/ kaitei/kaitei20070419.html#1
16. Press Release EMEA recommends new warnings and contraindications for ergot-derived dopamine agonists [Internet]. London: European Medicines Agency; c2008 [cited 2010 Aug 8]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ Press_release/2009/11/WC500015110.pdf
17. Tsuruta K, Kikuchi N, Kokan A, Kudo A, Nishiuma S, Sakakibara F. Physician's awareness of safety information on the risk of cardiovalvulopathy related to pergolide use in Japan. In: 9th Annual Meeting of International Society of Pharmacovigilance. Reims, France, 2009 Oct 6-9.
18. Lledó A, Dellva MA, Strombom IM, et al. Awareness of potential valvulopathy risk with pergolide and changes in clinical practice after label change: a survey among European neurologists. Eur J Neurol 14: 644-649, 2007.
19. Brown JS, Kulldorff M, Chan KA, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf 16: 1275-1284, 2007.
20. Kuwabara K, Matsuda S, Anan M, et al. Difference in resource utilization between patients with acute and chronic heart failure from Japanese administrative database. Int J Cardiol 141: 254-259, 2010.
21. Fukuda H, Imanaka Y, Ishizaki T, Okuma K, Shirai T. Change in clinical practice after publication of guidelines on breast cancer treatment. Int J Qual Health Care 21: 372-378, 2009.
22. Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol 20: 413-419, 2010.
23. Ikegami N, Campbell JC. Medical care in Japan. N Engl J Med 333: 1295-1299, 1995.
24. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 13: 1170-1185, 2006.
25. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 31: 1119-1123, 2008.
26. Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93: 3348-3356, 2008.
27. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 70: 104-108, 2009.
28. Waller E, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80: 1016-1020, 2005.
29. FDA News Release. FDA Announces Voluntary Withdrawal of Pergolide Products [Internet]. Rockville: U.S. Food and Drug Administration. c2007 [cited 2010 Aug 8]. Available from: http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ ucm108877.htm
30. Cease Sale of Permax® (pergolide mesylate) in Canada as of August 30, 2007 [Internet]. Eli Lilly Canada Inc. c2007 [cited 2010 Aug 8]. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/ advisories-avis/prof/_2007/permax_3_hpc-cps-eng.php
31. Leiyu S. Health Services Research Methods. 2nd ed. Delmar Pub, New York, 2007.
32. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 284: 3036-3039, 2000.
33. Jones JK, Fife D, Curkendall S, Goehring E Jr, Guo JJ, Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 286: 1607-1609, 2001.
34. Raschetti R, Maggini M, Da Cas R, Popoli P, Rossi A. Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy. JAMA 285: 1840-1841, 2001.
35. Cluxton RJ Jr, Li Z, Heaton PC, et al. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program. Pharmacoepidemiol Drug Saf 14: 1-9, 2005.
36. Willy ME, Manda B, Shatin D, Drinkard CR, Graham DJ. A study of compliance with FDA recommendations for pemoline (Cylert). J Am Acad Child Adolesc Psychiatry 41: 785-790, 2002.
37. Overhage JM, Tierney WM, Zhou XH, McDonald CJ. A randomized trial of "corollary orders" to prevent errors of omission. J Am Med Inform Assoc 4: 364-375, 1997.
38. Shojania KG, Jennings A, Mayhew A, Ramsay C, Eccles M, Grimshaw J. Effect of point-of-care computer reminders on physician behaviour: a systematic review. CMAJ 182: E216-E225, 2010.